肥満または過体重の日本人被験者を対象としたLY3841136の研究

基本情報

NCT ID: NCT06297616
ステータス: 完了
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 128
治験依頼者名: Eli Lilly and Company

概要

The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.

対象疾患

ObesityOverweight

介入

LY3841136(DRUG)

LY3841136-Placebo(DRUG)

Tirzepatide(DRUG)

Tirzepatide-Placebo(DRUG)

依頼者（Sponsor）

日本イーライリリー株式会社(INDUSTRY)

実施施設 (3)

P-One Clinic

Hachiōji, Tokyo, Japan

博多診療所

Fukuoka, Japan

医療法人　住田病院

Sumida-ku, Tokyo, Japan